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The incidence of head and neck squamous cell carcinoma (HNSCC) peaks between the ﬁfth
and  seventh decades of life. With prolongation of life expectancy, however, the proportion
of  elderly HNSCC patients is also increasing, which makes HNSCC in this life period an
important issue for healthcare providers. With features characteristic to the older patient
groups coupled with the inherent complexity of the disease, HNSCC in the elderly repre-
sents  a considerable challenge to clinicians. Indeed, to expedite the progress and improve
the  healthcare system to meet the needs of this unique population of patients, several essen-
tial  issues related to the clinical proﬁle, diagnostics, optimal treatment and support are of
concern and should be addressed in properly conducted clinical trials.
In  the present review, we analyzed a literature series comparing different age groups withRadiotherapy
Surgery
Systemic therapy
regard to their clinical characteristics, therapy, outcome and quality of life in an attempt
to  determine their implications on treatment-decision-making for elderly patients with
HNSCC.
©  2012 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All1.  Background
The population in developed countries is aging rapidly, which
is associated with a signiﬁcant increase in the total cancer
burden over the last decades and, speciﬁcally, also with an
increase in the incidence of the head and neck squamous cell
carcinoma (HNSCC) after 50 years of age1,2 (Table 1). Although
the age of most of the HNSCC patients ranges between 50 and
70 years, the occurrence of this tumor type in older patients
is not rare. Muir et al. estimated that as many  as 24% of the
HNSCCs are found in patients older than 70 years,3 whereas
Sikora reported for the period 1992–1999, establishing that
patients >74 years of age made up 19.5% of new cases in
1the SEER database. In Slovenia, the Cancer Registry data
has shown a continuous increase in the percentage of new
HNSCC cases diagnosed in the age group of ≥70 years: 17.9%
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in 1981–1990; 16.5% in 1991–2000; and 22.3% in 2001–20082
(Table 1).
2.  Aim
The aim of this review is to present the characteristics of
HNSCC in the elderly and to describe their implications on
treatment-decision-making.
3.  Who  is  actually  old?
The medical literature provides no clear deﬁnition of an
elderly person. According to the National Institute on Aging
and the National Institutes of Health, elderly persons can be
classiﬁed into three categories: young old – aged 65–75; old –
aged 76–85; and oldest old – older than 85 years.4 However,
blished by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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Table 1 – Incidence trends of the head and neck
squamous cell carcinoma in Slovenia, 1981–2008.
HNSCCa 1981–1990 1991–2000 2001–2008
All, per 100,000 19.3 21.3 21.4
≥50 years, % 81.5 79.1 83.3
≥70 years, % 17.9 16.5 22.3
≥75 years, % 9.5 8.3 12.2
HNSCC, head and neck squamous cell carcinoma.
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useful and cost-effective tool for an appropriate assignment ofPrimary tumor sites included: C00-C14, C32.
ost studies use the age of 70 years or 75 years as a cut-off
oint5–9 (Table 2).
Because aging is a highly individualized process and the
lderly population is very heterogeneous, chronological age
lone is an inappropriate parameter for treatment selection.
ore  important is functional age, which should be deﬁned
ndividually for each patient based on the functional status,
omorbidities and presence of geriatric syndromes.10,11
Several authors concluded that traditional oncology meas-
res of functional status alone (e.g. Karnofsky performance
tatus score) do not appear to reﬂect the comorbidity burden
nd its prognostic potential in elderly patients. A long-lasting
istory of tobacco and alcohol abuse that is characteristic for
 substantial proportion of HNSCC patients, an advanced age
er se, and the history of other factors or events increase the
robability for severe comorbidity. According to a literature
eview by Paleri et al., the prevalence of comorbidity in the
eneral population of HNSCC patients is approximately 60%,
hereas the rate of moderate and severe comorbid burden
s in the range of 20%.12 As may be expected, these ﬁgures
ise with age, impacting the prognosis of the patients signif-
cantly and independently from other factors. In the study of
anabria et al. conducted among 310 HNSCC patients aged
ver 70 years, 75.1% had at least one comorbid illness, which
as assessed as severe in 13.9% of these patients.13 In another
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study, the ﬁgures reported by Peters et al. for a group of 139
laryngeal carcinoma patients aged ≥75 years were 80% and
7%, respectively.14
In older patients with cancer, a full onco-geriatric evalua-
tion is warranted prior to any treatment-decision-making to
avoid overlooking any relevant information about the ability
of an older patient to cope with the proposed treatment. This
assessment is probably the most critical step, as its results
have a profound effects on all down-stream decisions (i.e. the
aim of treatment – palliation vs. curative, the extent of diag-
nostics and mode(s) of therapy employed) and, thus, also on
the prognosis. Numerous tools have been developed for a com-
prehensive assessment of older patients and the best example
seems to be the Comprehensive Geriatric Assessment (CGA)
(Fig. 1).11,15,16 Unlike other evaluation instruments, which
are mostly focused on some speciﬁc issues, the CGA uses
standardized instruments to employ a multidimensional
and interdisciplinary approach. The CGA encompasses a
spectrum of important clinical domains, namely an evalua-
tion of different aspects of patient functioning, comorbidity,
polypharmacy, nutritional status, cognitive function, socio-
economic issues and geriatric syndromes, thus allowing for
the identiﬁcation of patient groups with different frailty lev-
els and selection of the appropriate therapeutic strategy.11,15,16
Chaibi et al. reported on the results of the CGA of 161 patients
aged 73–97 years with different types of cancer. After the CGA,
geriatric intervention was proposed for 76% of patients and the
initial proposed anti-cancer treatment was changed in 49% of
cases.17 A report provided by the Curie Institute showed that
the treatment plan was modiﬁed in 38.7% of 93 cancer patients
after this assessment.18 Recently, a phase II prospective study
has demonstrated that a CGA-based stratiﬁcation of elderly
cancer patients is also of predictive value. It was found to be apatients to different treatment programs to achieve an optimal
balance between the effectiveness and toxicity of the proposed
therapy.19
tric Assessment – CGA.
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Table 2 – Clinical characteristics of HNSCC: comparison between elderly patients and younger age groups (only studies on different primary tumor sites and with >100
patients included in the elderly study group are presented).
Author
(year)Ref.
Time span N M:F ratio Primary tumor site, % Stage, % Treatment, % Outcome, % New PTs, %
Barzan et al.
(1990)5
1981–1984 438 OC vs. OPh vs. HPh vs. Lx
vs. others
I  vs. II vs. III vs. IV S/contraindications for S 5-Year OSa,b
<70 years 331 8.9:1 13 vs. 26 vs. 13 vs. 38 vs. 10 22 vs. 18 vs. 25 vs. 35 78/9 86 27
≥70 years 107 7.9:1 16  vs. 22 vs. 6 vs. 37 vs. 19 29 vs. 20 vs. 21 vs. 31 57/23 83 28
Sarini et al.
(2001)6
1974–1983 4610 OC vs. OPh vs. HPh vs. Lx I + II vs. III + IV/N0/M1 ST vs. SN vs. S + RT vs.
RT + ChT vs. ChT
5-Year OSc
<75 years 4337 25:1 33.8 vs. 29.4 vs. 14.5 vs. 22.3 29.8 vs. 37/52.1/2.8 27.4 vs. 35.6 vs. 22.3 vs. 14.1
vs. 17.6
25.1  17.5
≥75 years 273 0.2:1 39.9. vs. 26.7 vs. 8.8 vs. 24.6 31.1 vs. 37.9/59.7/0.7 13.9 vs. 15.4 vs. 9.7 vs. 0.2
vs. 5.5
16.5  8
Vaccher et al.
(2002)7
1975–1998 2143 OC vs. OPh vs. HPh vs. Lx I + II vs. III + IV/T3 + 4/N0/M1 Curative vs. palliative/S + RT
vs. RT + ChT
5-Year OSc/CSSb
<75 years 1962 10.3:1 28 vs. 19 vs. 13 vs. 39 vs. 39 vs. 16/41/54/2 71 vs. 21/29 vs. 10 44/59 n.r.
≥75 years 181 7.2:1 23 vs. 17 vs. 10 vs. 49 52 vs. 47/39/72/2 69 vs. 31 vs. 11 vs. 6 31/55 n.r.
Derks et al.
(2005)8
1998–2001 266 OC vs. Ph vs. Lx II vs. III vs. IV Standard vs. w/o TH 5-Year OSb,d
45–60 years 148 2.6:1 38 vs. 52 vs.10 18 vs. 20 vs. 63 89 vs. 4 38% n.r.
≥70 years 118 1.6:1 49 vs. 26 vs. 25 25 vs. 26 vs. 48 62 vs. 14 32% n.r.
Huang et al.
(2011)9
2003–2007 2312 OC vs. OPh vs. HPh vs. Lx 0–II vs. III + IV/T3 + 4/N0 Curative vs. palliative vs.
w/o TH
5-Year CSSc,e
<75 years 1860 2.7:1 19 vs. 26 vs. 5 vs. 21 30 vs. 64/43/42 93 vs. 5 vs. 2 75.4 n.r.
≥75 years 452 1.8:1 25 vs. 15 vs. 7 vs. 30 35 vs. 57/47/56 79 vs. 10 vs. 11 64.9 n.r.
Ref., reference; N, number of patients; M, male; F, female; PT, primary tumor; OC, oral cavity; OPh, oropharynx; HPh, hypopharynx; Lx, larynx; S, surgery; OS, overall survival; ST, surgery for the
primary; SN, surgery for the neck; RT, radiotherapy; ChT, chemotherapy; CSS, cause-speciﬁc survival; Ph, pharynx (oro- and hypo-); n.r., not reported; w/o TH, without therapy.
a Estimated from the Fig. 2 in the Ref. 5.
b P > 0.05.
c P < 0.05.
d Estimated from Ref. 32, Fig. 1.
e For patients who received deﬁnitive radiotherapy (N = 1487).
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Table 3 – Head and neck squamous cell carcinoma in the
elderly: clinical proﬁle.
Parameter In elderlya
Sex ratio Females > males
History of tobacco and alcohol abuse ↓
New primary tumors ↓
Primary tumor site Oral cavity and/or larynx, ↑
Hypopharynx, ↓
Disease stage T-stage, ↓ or comparable
N-stage, ↓
Survival (overall) ↓  or comparable
HPV-status ↓
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9↓, less frequent; ↑, more frequent; HPV, human papillomavirus.
a Compared to younger age groups.
While the CGA can be extremely helpful for physicians
ealing with elderly cancer patients, its value has not
een assessed speciﬁcally for HNSCC. Moreover, the CGA is
ime-consuming and, consequently, impractical for a routine
linical use. Shortened forms of CGA were proposed, although
heir validation in a routine clinical setting is needed.11,19,20
. Clinical  proﬁle  of  HNSCC  in  the  elderly
here are features distinctive for HNSCC patients of older age
roups (Table 3). First of all, in the elderly, there is a signiﬁ-
antly higher proportion of female patients compared to the
ounger population21 (Table 2). The reason for this is most
robably longer life expectancy among females. In addition,
 history of alcohol abuse and smoking is less frequently
eported in the advanced age groups than in the general pop-
lation of HNSCC patients. In the latter, the prevalence of
obacco and alcohol consumption is over 70%,22,23 whereas
mong elderly patients it is in the range of 40%.21,24–26 The
ame was reported by Barzan et al. for life-style related dis-
ases (e.g. chronic hepatitis, gastric and duodenal ulcer; 41%
s. 33%).5 This observation supports the theory that age alone
s a risk factor for HNSCC: the presence of risk factors resulted
n an earlier occurrence of malignancy, although it may also
ppear spontaneously in patients who  have not been exposed
o any of these factors as time passes. The possible mecha-
ism for age-related cancer is the accumulation of mutations:
he efﬁciency of DNA repair mechanisms may decrease with
ge, as may that of the immune system, resulting in a reduced
mmune surveillance against cancer cells. Due to a shorter
ife expectancy after the completion of treatment, the occur-
ence of secondary cancers is lower in elderly HNSCC patients
s compared with their younger counterparts,6 although the
pposite has also been reported in the literature.24
The most prevalent primary tumor sites in the head and
eck region in elderly patients seem to be – depending on
he series – the oral cavity or the larynx, each comprising
p to one half of all primaries, with the tendency to over-
ome their incidence among younger-aged patients. A trend
f fewer hypopharyngeal cancer cases in the elderly patient
21,24roup was also observed (Table 2). Considering the tumor
tage at presentation, it appears that the occurrence of an
dvanced disease (T3, T4) at the primary site is comparable to
r even reduced when matched with that observed in youngeriotherapy 1 8 ( 2 0 1 3 ) 16–25 19
age groups, but the regional lymphatics are primarily less fre-
quently inﬁltrated by cancer cells in older patients (Table 2).
Apparently, an increase in the disease severity that would
be expected from the usual delay in diagnosis in older peo-
ple, probably reﬂecting age-related inequalities in access to
health care due to a variety of social and behavioral factors,27
is successfully compensated by a less aggressive biology of the
disease in the elderly.28
There is no speciﬁc data on the role of the human papil-
lomavirus (HPV) in the HNSCC carcinogenesis of elderly
patients. However, summarizing the results from the pub-
lished studies that describe the HPV-positivity status in the
general population with HNSCC, it appears that HPV is not
an important factor or has only marginal signiﬁcance in the
etiology of HNSCC in elderly patients. Among other, the HPV
tumor positivity is typically associated with a clinical proﬁle
of a middle-aged white male having a higher socioeconomic
status and the oropharyngeal origin of the primary but no or
only low smoking history.29
5.  Treatment  concepts  for  the  elderly
The cornerstones in the treatment of patients with HNSCC
are surgery and radiotherapy (RT), often given in combi-
nation with one another and additionally intensiﬁed with
chemotherapy (ChT), recently also with targeted therapy
agents. Over the last decades, the treatment protocols for
HNSCC have become more  complex and aggressive with
the implementation of larger surgical resections requiring
reconstructions and a high-dose RT that employs altered
fractionation regimens and is administered in different com-
binations with systemic agents.
In several studies, age alone was found to be an impor-
tant factor for treatment selection. When compared with the
younger population with HNSCC, it was observed that elderly
patients are less likely to receive standard or curative treat-
ment (Table 2). As reported by Derks et al., after subdividing the
elderly group into two sets (aged 70–79 years and ≥80 years),
the proportions of patients receiving standard treatment in
the 45–60 years group and the other two  groups were 89%,
75% and 36%, respectively, whereas no treatment was given
to 4%, 13% and 18% of cases from the respective groups.8 Age
itself was listed speciﬁcally as a reason for not undergoing
the indicated therapy (surgery, RT or ChT) in the study by Ital-
iano et al.30 To continue, according to Ortholan et al., as much
as 59% of 200 patients aged ≥80 years and treated with cura-
tive intent (surgery and/or RT) received aged-adapted curative
treatment.25
On the other hand, many  studies showed that standard
treatment with curative intent can be safely performed in
elderly patients with a good performance status and with-
out severe comorbidities. Huang et al. reported no differences
in respect to unplanned RT interruptions, premature ter-
mination of the RT regimen or treatment-related deaths
between younger (aged <75 years) and older (aged ≥75
years) patients on deﬁnitive RT. Analyzing the data of 1307
patients included in the EORTC trials with RT, Pignon et al.
found that the age proﬁles of patients with and without
toxicity were similar, and neither locoregional control nor
nd ra20  reports of practical oncology a
survival were affected by age.31 A similar observation
regarding treatment-related complications was described in
several surgical series and for systemic therapy.5,32–35 As
reported by Peters et al., age was not recognized as an inde-
pendent prognosticator for treatment-related complications
in a group of 428 patients (aged ≥75 years, 32%) with laryn-
geal cancer after curative RT or surgery,14 as was the case
in the study by Milet et al. involving 261 patients (aged ≥70
years, 11%) with different primaries treated with upfront
surgery.21
Anyhow, elderly patients are underrepresented in non-
age-related clinical trials, and there is no sufﬁcient data
from high-quality phase III studies to guide the treatment
decision-making process for these patients. As outlined above,
a comprehensive oncogeriatric initial assessment of their
functional status and psychological proﬁle is crucial for the
selection of the most appropriate therapy or treatment com-
binations for the individual patient. Age alone should not be
used as a criterion to limit therapy. However, only elderly
patients in a good general condition following the initial
assessment should be considered candidates for curative
interventions. Bearing in mind that treatment could be harm-
ful, adequate supportive care must be provided in order to
improve patients’ compliance.
In the following sections, the main treatment modalities
used in HNSCC are discussed within the context of their rele-
vance to elderly patients.
5.1.  Surgery
The ﬁrst studies on aggressive surgical management of HNSCC
in elderly patients with a favorable outcome date back to the
1970s and 1980s. Mortality rates reported in these studies were
3.5% (aged >65 years) and 7.4% (aged >70 years) for elderly
patients vs. 0.8% and 1.4% for younger patients.36,37 The
authors urged that advanced age alone should not be a deter-
rent to performing aggressive surgical therapy for HNSCC;
careful preoperative evaluation of comorbidity and skillful
perioperative and postoperative management are mandatory.
The same conclusion was reached later by Clayman et al.,
who  reviewed the results of individualized surgical manage-
ment in a group of 43 HNSCC patients aged 80 years and
older.38 Comparison was made with patients younger than 65
years. Although the elderly patients had a higher frequency of
chronic diseases, complication rates were comparable (23.2%
vs. 20.2% for major; 27.7% vs. 22.6% for minor complications).
The elderly were more  likely to have systemic, i.e. pulmonary
and cardiovascular complications, whereas younger patients
more  frequently experienced local complications. There was
one postoperative death in the whole series, which occurred
in the group of elderly patients. Advanced age seemed to have
adversely affected local control, disease-speciﬁc survival and
overall survival. However, when compared with actuarial sur-
vival for the general population of the same age group, the
overall survival rates of elderly patients were similar. Results
of other smaller series support these observations.31,39
Reconstructive surgery using microvascular free tis-
sue transfer was also found to be feasible and safe in
elderly patients, but a higher incidence of perioperativediotherapy 1 8 ( 2 0 1 3 ) 16–25
complications, especially medical, was observed, which can
be attributed mainly to a higher prevalence of comorbidity
among older patients.40–45
Obviously, elderly patients have a higher perioperative
morbidity and mortality rates due to underlying coexisting
illnesses and often a poor performance status. Careful peri-
operative management is essential in order to reduce the
incidence of perioperative complications. Other important
parameters of concern when planning a major head and neck
surgery in elderly patients were identiﬁed as follows: male
gender (did worse), duration of the operative procedure and
extent of the procedure, which could be assessed through
disease stage or the need for, e.g. bilateral neck dissection
or reconstruction surgery.31,39,46 One option to minimize the
operative time is to adapt the surgical procedure by omitting
either reconstruction or (extensive) neck dissection. However,
both approaches must be weighed against the expected func-
tional and cosmetic outcome and the likelihood to achieve
a complete removal of the tumor. Deﬁnitive RT as an alter-
native to major surgery in high-risk patients should also be
considered.
5.2.  Radiotherapy
Preclinical studies evaluating the in vitro radiosensitivity of
human cells failed to show any age-associated differences.47
In the clinical setting, Pignon et al. reached the same con-
clusion. The authors reviewed acute and late toxicity in 1589
patients with HNSCC treated with RT alone, 26% of whom
were over 65 years old, enrolled in ﬁve EORTC phase III trials.31
The locoregional control and overall survival were comparable
across different age groups, which was also the case for objec-
tive mucosal reactions and weight loss. There was a statistical
difference in the distribution of functional mucosal reactions
(i.e. symptoms as experienced by the patient, directly related
to pain due to mucositis) with regard to age; this difference
existed for grade 3 and 4 side effects but not for grade 1 or 2
toxicities, which were more  frequent in older age groups. How-
ever, after adjusting for the WHO  performance status (elderly
patients scored signiﬁcantly higher), the occurrence of objec-
tive and functional mucosal reactions was quite similar for all
patients. The observed discrepancy in the distribution of acute
mucosal damage, which was independent of age, and severe
age-dependent functional reactions pointed to a decreased
tolerance for acute toxicity in the elderly. The occurrence
of late toxicity was independent of age. This study clearly
demonstrated that the effectiveness and toxicity of RT were
similar for all patients; as older patients tolerate less acute
toxicity compared to the younger ones, an appropriate selec-
tion of patients for radical and palliative RT regimens is of
utmost importance.
Other retrospective studies have also conﬁrmed that,
considering the ultimate outcome of treatment with RT and
the related toxicity, elderly patients are comparable to their
younger counterparts. Patients included in these studies were
aged 70 years and older9,48–50 and were irradiated mainly
with conventional fractionated schedules, although altered
fractionated RT regimens were also employed.51 RT was
found feasible also for the “oldest old” patients aged >85
years,25,30,52–55 although only a part of these patients (41%)
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ere to receive treatment delivered according to the insti-
ution’s policy, being age-adapted in 59% of them.25 It is
lso necessary to take note that postoperative RT could be
pplied to only 58% of patients with indications for adjuvant
rradiation.30 The multivariate analysis with a cut-off point of
4 years of age clearly distinguished between patients with
ore  (aged 80–84 years) and less (aged <80 years) favorable
utcome.25
In elderly patients, conventional fractionation (5 weekly
ractions of 1.8–2 Gy per day) seems to improve the most opti-
al  balance between efﬁcacy and toxicity. This is in line with
he results of the meta-analysis of 15 randomized trails com-
aring conventional RT and altered fractionated RT with 6515
atients included.56 A signiﬁcant beneﬁt in the overall sur-
ival (3.4% at 5 years, hazard ratio of 0.92) was observed with
ltered fractionation, and the overall beneﬁt was due to the
ffect on death related to cancer. Higher age inﬂuenced the
atients’ survival signiﬁcantly and adversely (hazard ratios of
.78 for those under 50 years old; 0.95 for 51–60 years old; 0.92
or 61–70 years old; and 1.08 for over 70 years old), which could
e attributed to an excess of deaths not related to cancer in
atients aged ≥71 years and a lower compliance and tolerance
o aggressive RT regimens in elderly patients.
In regard to the extent of irradiate volumes and dose for
lderly patients, no other recommendations could be made
eside those used in younger patients. Eventual adaptation of
hese two  parameters in order to reduce radiotherapy-related
ide-effects should base on the results of a well-designed
linical trial which have not been conducted yet. Retrospec-
ive series on age-adapted treatment with curative intent of
18 patients aged 80 years or more  with oral cavity SCC was
eported by Ortholan et al.25 An “adapted” treatment of opera-
le tumors included deﬁnitive radiotherapy instead of surgery,
mission of postoperative irradiation in high-risk patients, no
eck dissection or irradiation when required, and implemen-
ation of unconventional fractionation regimens and reduced
adiotherapy doses. Although treatment adapted to age was
ot associated with reduced disease-speciﬁc survival or over-
ll survival in this study, the omission of elective lymph node
reatment in stage I–II tumors increased the rate of regional
ecurrence from 6% to 36% (P = 0.01). Again, proper selection
f patients for curative treatment, including radiotherapy,
ppears to be the most critical step in the management of
lderly patients with HNSCC.
Considering the fact that elderly patients have a lower abil-
ty to tolerate the acute toxicity of irradiation, active support is
andatory, including mucosal hygiene measures, pain control
nd early nutrition intervention. Recent technological devel-
pments in the ﬁeld of RT are also expected to exert a positive
ffect on the toxicity proﬁle in irradiated patients.57,58 The
bility of sophisticated RT techniques, primarily the intensity-
odulated RT, to shape the high-dose volume according to
he 3-dimensional outline of the target(s) and to improve
he control of dose deposition in nearby structures, which
re not inﬁltrated with cancer cells, allows a better preser-
ation of their function. Recently reported clinical results on
he use of IMRT  planning aimed to spare parotid glands and
he non-involved parts of the swallowing apparatus during
he optimization process can be considered as a proof of the
rinciple.59,60iotherapy 1 8 ( 2 0 1 3 ) 16–25 21
Elderly patients who were considered in the pre-therapy
assessment to be too fragile to cope with a lasting and
intensive curative RT should be directed to shorter and less
aggressive palliative regimens. Several different palliative
schedules are in use for HNSCC patients, all reporting high
rates of locoregional responses and symptom relief as well as
a favorable compliance.61–64 If the tumor responses favorably
and the patient’s general status has improved signiﬁcantly
after palliative irradiation, additional fractions of RT could be
given to convert the palliative intended treatment into a cura-
tive one to increase the likelihood for obtaining local control
of the disease.
5.3.  Chemotherapy
Prospectively collected data on the toxicity and efﬁcacy of ChT
in elderly patients is limited. With regard to the proportions
of older patients (aged >70 years) in larger phase III ChT tri-
als, they are either not recruited at all65,66 or their number is
not presented67,68 or is negligible (<10%, Ref. 69), as was the
case in a recently updated meta-analysis of ChT in HNSCC (RT
alone vs. concomitant RT + ChT, 7% vs. 8%).70 It is necessary
to stress that in the latter the age was the only patient char-
acteristic affecting survival: the beneﬁt of concomitant ChT
was smaller in older patients. The authors tried to explain this
observation with a higher tendency of older patients to die
from other causes that their HNSCC; the ChT-related increase
in non-cancer deaths in this group might be another rea-
son. An argument for this explanation was given by Machtay
et al. who analyzed three previous RTOG trials on concurrent
radiochemotherapy for factors associated with the occurrence
of late toxicity. Out of 230 assessable patients (12% of them
in the age group of 71–78 years), 43% suffered from a severe
late toxicity; older age was recognized as a signiﬁcant variable
correlated with its development on multivariate analysis with
the odd ratio of 1.05 per year.71 Also, in a combined analy-
sis of two phase III ECOG trials on palliative cisplatine-based
chemotherapy with a total of 13% patients aged ≥70 years,
Argiris et al. found no difference in the objective response
rate (28% vs. 33%) and the median time to progression (5.25
vs. 4.8 months) between elderly and younger patients. How-
ever, there was a trend of a poorer survival outcome at 1 year
(26% vs. 33%) and a higher rate of toxic deaths (13% vs. 8%) in
the older group with a signiﬁcantly higher incidence of grade
3–5 nephrotoxicity, diarrhea, and thrombocytopenia.72
On the other hand, the results from retrospective studies
suggest that the ability of older patients to cope with ChT is
comparable to younger ones, particularly when adequate sup-
portive care is provided.34,35 Due to a selection bias regarding
patients’ recruitment into retrospective studies, these results
can hardly be applied to the general population. The physio-
logical changes associated with the process of aging resulted
in alterations in the pharmacodynamics and pharmacoki-
netics of the drugs applied. Together with the increased
susceptibility of the normal tissue to their activity, they may
signiﬁcantly increase the rate of toxic complications and have
a detrimental effect on the patient’s ability to tolerate ChT.73
The idea to circumvent a diminished tolerance of elderly
patients to ChT by reducing its dose intensity was tested by
Schnider et al.74 The authors grouped 71 patients with HNSCC
nd ra22  reports of practical oncology a
by their age into three cohorts: 54 patients aged 70–79 were
treated with a standard dose of cisplatin (100 mg/m2/day 1)
and 5-FU (1000 mg/m2/day administered in continuous infu-
sion for 5 days), whereas in those aged 80–84 the ChT dose was
reduced by 20% and by 30% in patients older than 85 years (17
patients in total). The objective response rate was 79% (52% of
complete responses) for the ﬁrst cohort and only 31% (6% of
complete responses) for those aged 80 years and older. This
study clearly demonstrated that reduction in the ChT dose
seriously compromises the efﬁcacy of treatment.
5.4. Target  therapy
At the moment, cetuximab is the only molecular targeting
agent routinely used to treat HNSCC. In registration studies,
it was found effective and well tolerated, both in the con-
comitant setting with RT in patients with a locoregionally
advanced HNSCC75 and in combination with platinum-based
ChT as a ﬁrst line treatment in patients with a recurrent or
metastatic HNSCC.76 Considering its use in elderly patients,
several points should be noted. Firstly, older patients (aged ≥65
years) represented only a small proportion of those included
in the experimental arm in either of the two studies: 19% in
Bonner’s study and 21% in Vermorken’s study.75,76 Further-
more, with the accumulation of clinical experience with the
drug in a routine setting, it seems that its toxicity, particularly
when combined with RT, is more  pronounced than reported
in the above mentioned studies. Bonner et al. reported no
difference in grade 3–5 radiation mucositis (52% vs. 56%) or
dermatitis (18% vs. 23%) between the RT alone arm and the
RT-cetuximab arm.75 Giro et al. who conducted a survey on the
use of cetuximab and concurrent RT in EORTC centers reported
a 49% incidence rate of grade 3–4 radiation dermatitis.77 The
Australian experience with concurrent cetuximab and RT in
13 elderly HNSCC patients (median age 68 years, range 52–82
years) is even more  alarming: the authors observed a high rate
of toxicity (both grade 3–4 radiation mucositis and dermatitis
in 10 out of 13 patients), low treatment compliance and delays
in completing RT. Only 4 out of 12 patients (33%) managed to
complete the planned 8 cycles of cetuximab.78 Finally, updat-
ing the original data, Bonner et al. found the combination
of RT and cetuximab beneﬁcial only in distinct sub-groups:
in patients aged less than 65 years, with a high Karnofsky
performance status (90–100) and a prominent skin rush. In
less ﬁt and/or elderly patients or in those without or with
a mild skin reaction, the effect of combined treatment was
comparable to RT alone.79 Also in the randomized study on
metastatic/recurrent HNSCC, older patients (aged ≥65 years)
and those with a low Karnofsky index (<80) did not bene-
ﬁt from the addition of cetuximab to platinum–ﬂuorouracil
ChT.76 Although the patient numbers in these subgroups were
small and the results might represent spurious ﬁndings, they
are highly provocative and require further investigation.
More  encouraging data was presented by Jensen et al. (73
patients, median age 69 years) and Alongi et al. (22 patients,
median age 73 years), who  found concomitant administra-
tion of cetuximab with RT feasible, with manageable toxicity
and of promising activity.80,81 At the moment, the limited data
regarding the use of cetuximab in elderly patients, especiallydiotherapy 1 8 ( 2 0 1 3 ) 16–25
when administered with RT, do not allow a ﬁrm conclusion to
be drawn.
6.  Survival  of  elderly  patients  with  HNSCC
As in other types of cancer, the prognosis of HNSCC patients
is age-related and is poorer in the elderly82 (Table 2). Analyz-
ing the joint French Cancer Registry database, Colonna et al.
found an excess mortality rate in HNSCC patients aged >75 at
the time of diagnosis compared to younger age groups.83 This
may be attributed to frailty of older patients with impaired
ability of the immune system to generate an efﬁcient response
against tumors and a poorer tolerance to the applied thera-
pies, which are often less aggressive and, consequently, less
effective. A more  advanced disease at presentation is proba-
bly not the reason for the observed differences in age-related
survival of HNSCC patients (Table 2). It is necessary to take
note that excess mortality was observed mainly at the begin-
ning of a follow-up, whereas no effect of age was seen in
the period between 1 and 3 years after the diagnosis (but
re-appeared later). The decline in excess mortality over time
could be explained by patient selection that occurs earlier in
elderly patients than in younger ones, most probably due to
the initial frailty of the former.
The survival difference between age groups is signiﬁcantly
reduced or even eliminated with a more  balanced compari-
son (Table 2). For example, Bhattacharyya analyzed the SEER
database for the years 1988–1998 using random matching
of each case from the elderly cohort (aged ≥70 years) with
younger cases (aged <70 years) on gender, year of diagnosis,
cancer stage, the extent of surgery and RT to create a reference
group.84 With a controlled analysis, the author eliminated the
potential bias that elderly patients under consideration were
treated with a less aggressive surgical or radiation therapy
compared to younger patients. Three distinctive primary sites
were analyzed: glottis larynx, oral tongue and palatine ton-
sil. A signiﬁcant difference in the overall mean survival and a
disease-speciﬁc survival (although small in magnitude) were
recorded for glottis and tongue carcinomas but not for tonsil
carcinoma. After stage stratiﬁcation, however, the overall and
disease-speciﬁc survivals were comparable between the two
age cohorts for all three tumor sites. Similarly, no indepen-
dent prognostic value of age was found by van der Schroeff
et al. for mortality after making an adjustment for the tumor
stage, comorbidity burden and treatment intent.33
7. Quality  of  life  issue  in  the  elderly
Several studies conﬁrmed that the quality of life (QoL) in
elderly patients with HNSCC suitable for curative treat-
ment programs appeared to be at least comparable to the
one of younger patients when a global health-related QoL
is considered.33,85–88 Opposite results were also reported,89which could be explained in part by the inﬂuence of gen-
der (female scored worse) and/or tumor site (patients with
laryngeal tumors described more  signiﬁcant problems) on QoL
perceptions.87
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A positive effect on QoL is probably not inﬂuenced only by
he general view of older patients that they have less to lose
s a consequence of their cancer and the related treatment;
lso, their expectations might be less comparable to the ones
f the younger counterparts. For example, when Rogers et al.
ompared the results of a QoL survey undertaken in surgical
atients with oral and oropharyngeal cancer to the national
eference data, the young patients cohort (aged <60 years)
eared signiﬁcantly more  than expected for their age, which
as not the case with older patients.90 Recently, Laraway
t al. reported QoL data for 638 patients obtained one year
fter curative treatment for oral SCC.88 In many  domains, the
ealth-related QoL scores were higher among older patients
aged ≥65 years) compared to those of younger patients.
Investigating prospectively the coping and locus of con-
rol strategies in HNSCC patients, Derks et al. recognized that
here were differences in the coping styles and locus of control
echanisms used by older and younger patients.91 However,
hese variances did not result in differences in the QoL and
epressive symptoms after treatment, which conﬁrms that
lderly patients can cope and adapt to a disease and therapy
urprisingly well.
Finally, technological advances could also be expected
o provide positive effect on the QoL. As shown by Huang
t al., who conducted a QoL survey among 307 HNSCC sur-
ivors treated with two-dimensional RT, three-dimensional
T or intensity-modulated RT, more  advanced RT techniques
esulted in a better QoL outcome, especially on swallowing-
elated QoL scales.92
. Conclusion
he burden of cancer in the elderly population is high and
ill increase further, especially in developed countries. There
s a considerable body of evidence that older patients cope
ell with and adjust successfully to the disease and therapy;
hus, chronological age alone should not be the only factor
onsidered in the treatment decision-making process. Other
arameters are also important, namely the functional status,
omorbidity burden, polypharmacy, nutritional status, cogni-
ive function, socio-economic issues and geriatric syndromes,
hich should be evaluated in a multidisciplinary setting
efore initiating any treatment. According to the available
ata, surgery and RT are feasible, effective and well tolerated
lso in elderly patients in a good performance status and with-
ut severe comorbidities. Further investigations are warranted
o determine the role of ChT, target therapies and combined
odality therapies in patients of advanced age groups.
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